Aricept may cause mild side effects other than those listed above. See the drug’s prescribing information for details. * To learn more about this side effect, see the “Side effects explained ...
Researchers at Harvard University’s Wyss Institute for Biologically Inspired Engineering have discovered a potential ...
Aricept (donepezil) is a brand-name drug prescribed for dementia related to Alzheimer’s disease. Aricept has interactions with other drugs and certain supplements. Examples include ...
Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...
"Donepezil has been used worldwide by patients ... This study demonstrates that an encapsulated version of the drug could potentially be used in the future to buy patients critical time to survive ...
said that patients taking Aricept in the latest trial showed a statistically significant improvement in cognitive function, compared with those taking placebos. On the other hand the drug is ...
The FDA has since approved three drugs for the treatment of mild to moderate AD: Donepezil (Aricept) was approved in 1996, Rivastigmine (Exelon) was approved in 2000, and galantamine (Reminyl) was ...
Donepezil is the drug most frequently used to treat cognitive symptoms in Alzheimer disease. This study evaluates the effects of donepezil on obstructive sleep apnea in patients with Alzheimer ...
Ritalin, the first drug to treat attention deficit hyperactivity ... showed that a small group of middle-aged pilots given Aricept did better on flight simulation tests compared with those given ...
Consequently, combination therapy currently involves the administration of one cholinergic drug (donepezil, galantamine or rivastigmine) and one glutamatergic drug (memantine). There have been no ...
They tried memantine and Aricept, drugs for moderate to severe Alzheimer’s that can help with confusion and memory loss. Neither drug helped, and the side effects were intolerable. Today ...
Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the CTAD 2024 conference. Read why ...